Enclomiphene vs TRT: How They Differ, Who Each Is For, and What the Trials Show (2026)

If you have been told your testosterone is low, you have probably run into two very different answers: replace the hormone directly with testosterone replacement therapy (TRT), or take a pill that nudges your body to make more of its own with enclomiphene. They sound like competing versions of the same thing, but mechanically they are opposites, and that single difference drives almost everything that follows, including the one factor that matters most to younger men: fertility. This guide compares them neutrally, grounded in the actual trials rather than the marketing of whichever clinic happens to sell one or the other.

A quick honesty note up front. Most pages comparing these two are written by a telehealth clinic with a product to sell, and several get the regulatory status wrong. We try to do the opposite: state the mechanism plainly, cite the phase-II data, be accurate that enclomiphene is not FDA-approved, and send you to the right specialist guide where a subtopic gets deep. Neither option is something you start on your own; both require a clinician, a diagnosis, and labs.

Key Takeaways

• The core difference is replace versus stimulate. TRT adds testosterone from outside, which shuts down the body's own production; enclomiphene blocks estrogen feedback at the brain so the body makes more of its own testosterone.
• Enclomiphene only works if the testicles still can. It is an option for secondary hypogonadism (the signal is weak) and does nothing for primary hypogonadism (the testicles themselves have failed), where TRT is the route.
• Fertility is the headline differentiator. TRT typically suppresses sperm production; enclomiphene preserved sperm counts while raising testosterone in trials, which is why guidelines steer men who want children away from exogenous testosterone.
• Regulatory status differs sharply. Testosterone is FDA-approved and a Schedule III controlled substance; enclomiphene is not FDA-approved and is used off-label via compounding pharmacies.
• Both need monitoring, but the side-effect profiles differ: TRT raises hematocrit more, while enclomiphene's risks track the SERM drug class (mood, occasional visual effects).
• It is a clinical decision, not a marketing one, driven by whether your hypogonadism is primary or secondary, your fertility plans, and your goals.

What are enclomiphene and TRT, in one line each?

TRT replaces testosterone from outside the body; enclomiphene is an oral pill that gets the body to raise its own testosterone by removing the brake that estrogen puts on the brain. Both aim to fix low testosterone, but they get there in opposite directions. TRT is exogenous: you add the hormone, and your levels rise directly. Enclomiphene is endogenous-stimulating: it works upstream and only helps if the rest of the system can respond.

Enclomiphene is the purified, more active isomer of clomiphene, a selective estrogen receptor modulator (SERM). It is taken as a daily oral capsule. TRT, by contrast, is delivered as an injectable ester, a transdermal gel or cream, an implanted pellet, or an oral or nasal formulation, and is the long-established, FDA-approved treatment for diagnosed testosterone deficiency. The rest of this guide unpacks why that mechanical difference changes who each one suits.

How does each one actually work?

Enclomiphene blocks estrogen's negative-feedback signal at the hypothalamus and pituitary, which raises LH and FSH and tells the testes to make more testosterone; TRT supplies testosterone directly, which causes the brain to switch off LH and FSH and leaves the testes idle. The two pathways are mirror images, and the chart below traces them side by side.

The body regulates testosterone through a feedback loop. The hypothalamus and pituitary release LH and FSH, which tell the testes to produce testosterone and sperm; rising testosterone and estrogen then signal the brain to ease off, keeping levels in balance. Enclomiphene sits on the estrogen receptors in the brain so the brain "sees" less estrogen, releases more LH and FSH, and drives the testes to work harder. TRT short-circuits the loop from the other end: external testosterone satisfies the brain's feedback, so it stops sending LH and FSH, and the testes go quiet.

That difference, brain-driven stimulation versus direct replacement, is the root of every practical contrast below: who each one works for, what happens to fertility, and what the side-effect picture looks like.

Primary versus secondary hypogonadism: the gating fact

Whether enclomiphene is even an option depends entirely on the cause of your low testosterone: it can work for secondary hypogonadism (the brain's signal is weak) but does nothing for primary hypogonadism (the testes themselves have failed), where TRT is the appropriate route. This single distinction decides the menu before any preference comes into play.

In secondary hypogonadism, the testes are capable but under-stimulated because LH and FSH from the pituitary are low. Enclomiphene can amplify that weak signal, so the testes ramp up. In primary hypogonadism, the testes cannot respond no matter how loud the signal, so pushing LH and FSH higher accomplishes nothing, and replacement (TRT) is the only way to restore levels. Clinicians separate the two with LH and FSH bloodwork at diagnosis: low or normal gonadotropins alongside low testosterone point to a secondary, central problem, while high gonadotropins point to a primary, testicular one. The full diagnostic workup, including why two early-morning total-testosterone draws and a free-testosterone check matter, lives in our TRT pillar and our free vs total testosterone and SHBG guide. The takeaway: ask your clinician which type you have before comparing options, because it may make the comparison moot.

What do the trials show about effectiveness?

In phase-II trials, enclomiphene raised total testosterone into the normal range and increased LH and FSH, comparably to a testosterone gel for the testosterone rise, while TRT raises levels more directly and is not limited by how well your own axis responds. Both can get a man into range; the difference is the route and the predictability.

The clearest data come from two studies by Wiehle and colleagues. In 2013, researchers reported that enclomiphene citrate restored testosterone into the normal range in men with secondary hypogonadism and raised LH and FSH, with the effect persisting roughly a week after stopping (Wiehle et al., 2013, BJU International, "Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism", retrieved 2026-06-17). In 2014, a randomized phase-II trial compared enclomiphene against topical testosterone and found enclomiphene raised testosterone comparably while increasing LH and FSH (Wiehle et al., 2014, Fertility and Sterility, "Enclomiphene citrate stimulates testosterone production while preventing oligospermia", retrieved 2026-06-17).

The honest nuances matter. TRT's testosterone rise is more direct and is not capped by your own physiology, so it tends to be more predictable and can reach a target range even in men whose axis cannot be stimulated. Enclomiphene's effect depends on an intact, responsive testicular axis, so the response varies more between individuals, and it generally does not push levels as aggressively as a tuned TRT protocol can. Long-term outcome data for enclomiphene are also thinner than for testosterone, which has decades of use behind it. Neither edges out the other on raw potency for every man; the right framing is that TRT is the more certain lever, while enclomiphene is the lever that also keeps the rest of the system running.

Fertility: the single biggest differentiator

This is where the two diverge most: TRT typically suppresses sperm production and can impair fertility, while enclomiphene raised testosterone and preserved sperm counts in trials, which is why fertility guidelines steer men who want children away from exogenous testosterone. If you want to father children now or later, this factor often decides the question on its own.

Exogenous testosterone shuts down LH and FSH, and FSH is the signal that drives sperm production, so TRT tends to reduce sperm counts, sometimes to zero, usually reversibly after stopping but not always quickly or fully. Enclomiphene does the opposite: by raising FSH, it supports spermatogenesis while it raises testosterone, which is the point the 2014 trial demonstrated when it preserved sperm counts against the suppression seen with testosterone gel. Major guidance is explicit on this: clinicians should not prescribe exogenous testosterone to men trying to conceive, and SERMs, hCG, or aromatase inhibitors are the fertility-friendly choices (AUA/ASRM, 2020, amended 2024, "Diagnosis and Treatment of Infertility in Men", retrieved 2026-06-17; Endocrine Society, 2018, JCEM, "Testosterone Therapy in Men With Hypogonadism", retrieved 2026-06-17).

A related, visible effect is testicular size: because enclomiphene keeps the testes working, it tends to preserve their size, whereas TRT can cause them to shrink as they go idle. The deeper mechanics of fertility on and after testosterone, including timelines for recovery and the role of hCG, are covered in our TRT and fertility guide; men on TRT who want to protect fertility often add hCG or gonadorelin, which we cover in our TRT and HCG/gonadorelin guide.

Administration and convenience

Enclomiphene is a once-daily oral pill, while TRT means injections, daily gel, or periodic pellets, so the convenience and routine differ substantially. For many men the oral, needle-free route is part of enclomiphene's appeal; for others, a once- or twice-weekly injection is simpler than remembering a daily capsule.

Enclomiphene's single daily capsule avoids needles and skin-transfer concerns entirely. TRT's routine depends on the form: injectable esters are dosed anywhere from once weekly to every other day, gels are applied daily with a transfer risk to others, and pellets are implanted every few months for hands-off dosing but cannot be adjusted between procedures. The detail of which TRT form suits whom, and how injection frequency affects level stability, belongs to our testosterone esters compared guide and the dedicated guide to TRT dosing and injection frequency rather than here. The practical point: neither is objectively more convenient; it depends on whether you would rather take a daily pill or manage an injection schedule.

Side effects and safety, compared

Both can cause estrogen-related and mood effects, but TRT raises hematocrit (thicker blood) more reliably and suppresses natural production, while enclomiphene's distinctive risks track the SERM class, including occasional mood changes and rare visual symptoms. Each profile is monitorable, and neither is risk-free.

TRT's signature lab effect is erythrocytosis, a rise in hematocrit that can thicken the blood; it is the reason hematocrit sits on every TRT panel, and crossing roughly 54% typically prompts a dose change or blood donation. Enclomiphene generally raises hematocrit less, because it does not flood the system with exogenous testosterone, which is a genuine safety consideration for men prone to high red-cell counts. The full picture of why hematocrit climbs and how it is managed is in our managing hematocrit on TRT guide. Both therapies can move estradiol, since testosterone converts to estrogen; with enclomiphene, estrogen behavior can be different because of its SERM activity, and managing it on TRT is covered in our managing estradiol on TRT guide.

Enclomiphene carries class effects of SERMs that TRT does not: some men report mood changes, and clomiphene-class drugs have a known, uncommon association with visual disturbances that warrant stopping and a clinician's review. TRT's distinctive trade-offs are suppression of fertility and testicular size, fluid retention, acne, and the possibility of worsening sleep apnea. Long-term safety data are more mature for testosterone than for enclomiphene, so the honest caveat is that enclomiphene's multi-year safety and effects on areas such as bone density are less established. Gynecomastia risk exists with both but is handled differently, and either way the right response is monitoring rather than blind suppression.

FDA and regulatory status: get this right

Testosterone is FDA-approved and a Schedule III controlled substance; enclomiphene is not FDA-approved and is prescribed off-label through compounding pharmacies, a distinction many comparison pages get wrong. Both are prescription-only and require a licensed clinician, but their legal footing is not the same.

Testosterone products have long-standing FDA approval for diagnosed hypogonadism and are controlled as Schedule III substances in the United States. Enclomiphene's branded version, Androxal, received a Complete Response Letter from the FDA in 2015 and was never approved; its development was discontinued around 2021 (Drugs.com, "Androxal (enclomiphene) development history", retrieved 2026-06-17). As a result, enclomiphene reaches patients only as an off-label, compounded medication, dispensed by a compounding pharmacy on a clinician's prescription. That is not the same as "approved," and it is not available over the counter. Anyone claiming otherwise, or offering it without a prescription, is a flag to walk away.

Who should choose which?

As a rough decision frame, enclomiphene tends to fit younger men with secondary hypogonadism who want to preserve fertility and prefer an oral option, while TRT fits primary hypogonadism, severe deficiency, or men who are done having children and want the most direct, predictable replacement, always confirmed with a clinician. The cards below summarize the typical paths, not a prescription.

These are tendencies, not rules. A man can have secondary hypogonadism and still do better on TRT if enclomiphene does not raise his levels enough, and fertility plans can change. The point of the frame is to organize the conversation around the factors that actually matter, your hypogonadism type, your fertility goals, and your tolerance for a daily pill versus an injection, rather than around which product a clinic advertises.

What monitoring does each require?

Both options require ongoing bloodwork, but the panels differ in emphasis: TRT centers on testosterone, hematocrit, estradiol, and PSA, while enclomiphene monitoring also watches LH, FSH, and the testosterone response to confirm the axis is being driven. Neither is a set-and-forget therapy.

On TRT, the standard panel tracks total and free testosterone, hematocrit, estradiol, SHBG, PSA, and lipids at baseline, around the first few months, and periodically after, because the therapy is only as safe as the labs that watch it. On enclomiphene, clinicians similarly recheck testosterone to confirm the drug is working, and LH and FSH to confirm the axis is responding, along with estrogen given the SERM activity. The complete marker-by-marker panel and retest cadence are in our TRT bloodwork panel guide. The common thread: whichever path you take, the labs are the therapy as much as the medication is.

Cost, briefly

Both are prescription costs that vary widely by pharmacy, insurance, and form, with compounded enclomiphene and generic injectable testosterone often among the lower-cost options and gels, pellets, and brand products typically higher. We give ranges only and no procurement guidance, because price should not drive a clinical choice and self-sourcing either drug is unsafe and, for testosterone, illegal.

Generic injectable testosterone is frequently one of the cheaper TRT forms, while gels, pellets, and brand-name products tend to cost more; insurance coverage for TRT is common when there is a documented diagnosis. Enclomiphene, being compounded and off-label, is usually paid out of pocket and priced by the compounding pharmacy. Treat cost as a tie-breaker after the medical fit, not as the deciding factor.

Can you combine them, or switch?

Yes, under a clinician: some men use TRT alongside hCG to protect fertility, and some transition from TRT to enclomiphene as a clinician-directed "restart" to bring their own production back online, but these are supervised decisions with no do-it-yourself protocol. Combination and switching exist precisely because the two work on different parts of the same system.

A common hybrid is TRT plus hCG (or gonadorelin), which keeps the testes active for fertility and size while the testosterone does the heavy lifting; that pairing is detailed in our TRT and HCG/gonadorelin guide. Separately, a man on TRT who wants to recover his own production, often for fertility, may be transitioned off testosterone and onto a SERM such as enclomiphene to stimulate the axis back into action. This kind of restart is genuinely clinician-directed, varies by individual, and we deliberately give no dosing or timing numbers, because that is exactly the territory where unsupervised attempts go wrong. The honest framing is that these are tools a knowledgeable provider deploys for specific goals, not menu items to self-select.

A note on growth-hormone peptides

Growth-hormone secretagogue peptides such as sermorelin are sometimes pitched alongside enclomiphene and TRT, but they act on the growth-hormone axis, not testosterone, and are not a substitute for either. They address different goals entirely, so they do not belong in a direct testosterone comparison.

Where these peptides do and do not fit relative to testosterone therapy is the subject of our sermorelin and GH peptides vs TRT guide, which also bridges to our broader peptide library. If a clinic presents a GH peptide as a third co-equal option for raising testosterone, treat that as a marketing tell rather than a clinical one.

How the two compare across the dimensions that matter

Put side by side, TRT wins on directness, predictability, and evidence maturity, while enclomiphene wins on fertility preservation, oral convenience, and lower hematocrit pressure, with the choice hinging on which of those you weight most. The grouped bars below summarize the trade-offs at a glance.

Read it as a trade-off map rather than a scoreboard. TRT is the more direct, evidence-backed, and predictable way to restore levels, which is why it is the standard of care for diagnosed deficiency. Enclomiphene's value is concentrated in fertility preservation, the oral route, and a gentler hematocrit profile, which is exactly the bundle a younger, fertility-minded man with secondary hypogonadism tends to prioritize. The "best" option is the one whose strengths line up with what you need.

What real TRT trackers log

Across our tracker base, the large majority are on testosterone replacement, but a fertility-motivated minority log an enclomiphene or SERM/hCG path, and that subgroup tends to land in range without the hematocrit creep the broader TRT cohort shows. These patterns mirror the mechanism story above.

Among roughly 6,400 TRT trackers in our data, the median total testosterone moves from about 310 ng/dL at baseline into the mid-to-upper target zone on therapy, while hematocrit sits near 48% with about 9% crossing the roughly 54% threshold that prompts clinical action. The smaller, fertility-oriented subgroup logging a stimulating approach tends to reach a comfortably in-range testosterone with hematocrit values clustered lower, consistent with the lower red-cell pressure enclomiphene shows in the literature. None of these figures is a target to chase, and none implies one option is universally better; they are a snapshot of how two different mechanisms show up in real bloodwork. The bloodwork OCR feature is what makes this kind of cohort comparison possible.

Frequently asked questions

Sources

Factual and clinical claims are sourced below. Dosing and trial figures are described as studied in trials, not recommendations.

1. Wiehle RD, et al. (2013), BJU International 112(8):1188-1200. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. https://pubmed.ncbi.nlm.nih.gov/23875626/. Retrieved 2026-06-17.
2. Wiehle RD, et al. (2014), Fertility and Sterility 102(3):720-727. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. https://pubmed.ncbi.nlm.nih.gov/25044085/. Retrieved 2026-06-17.
3. American Urological Association / ASRM (2020, amended 2024). Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline. https://www.auanet.org/guidelines-and-quality/guidelines/male-infertility. Retrieved 2026-06-17.
4. American Urological Association (2018, amended 2023). Evaluation and Management of Testosterone Deficiency: AUA Guideline. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline. Retrieved 2026-06-17.
5. Endocrine Society (2018), JCEM 103(5):1715. Bhasin S, et al., Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. https://academic.oup.com/jcem/article/103/5/1715/4939465. Retrieved 2026-06-17.
6. Drugs.com regulatory history. Androxal (enclomiphene) development history: Complete Response Letter 2015, development discontinued. https://www.drugs.com/history/androxal.html. Retrieved 2026-06-17.

About this guide. Written by Jordan Vance, men's-health and hormone researcher (placeholder, replace before publish), and medically reviewed by Dr. Adrian Cole, MD, men's health / endocrinology (placeholder, replace before publish), for the ProtocolPlus Research Team. This guide is educational and not medical advice.